On the basis of these mechanistic findings, we test for potential actionable metabolic vulnerabilities by targeting Cav-1-mediated lipid scavenging and metabolism in a mouse model of aggressive prostate cancer. This evidence concerns the gene CAV1 and prostate cancer.